From: Joern Loetsch j.loetsch@em.uni-frankfurt.de
Subject: [NMusers] NONMEM sparse data advantage reference
Date: Thu, 02 Nov 2006 07:22:31 +0100

Dear NONMEM users, The NONMEM approach is especially better than the
two-stage approach to estimate the PK of some drug in a sparse data
situation. Not speaking of its other advantages.
I fail to remember a reference for this.
Could you please help me out.
Thank you in advance.
Jörn Lötsch

-- 
_______________________________________________________
Univ.-Prof. Dr. med. Jörn Lötsch
pharmazentrum frankfurt/ZAFES
Institut für Klinische Pharmakologie Johann Wolfgang Goethe-Universität Theodor-Stern-Kai 7 D-60590 Frankfurt am Main

Tel.:069-6301-4589
Fax.:069-6301-7636
http://www.klinik.uni-frankfurt.de/zpharm/klin/

_______________________________________________________

From: Nitin Mehrotra nitin_utmem@yahoo.com
Subject: Re: [NMusers] NONMEM sparse data advantage reference
Date: Thu, 2 Nov 2006 06:52:21 -0800 (PST)

Dear Joern,

You might want to look at the following references:
  
1:   Ette EI, Williams PJ, Lane JR.                
Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.
Ann Pharmacother. 2004 Dec;38(12):2136-44. Epub 2004 Oct 26. Review. 
PMID: 15507495 [PubMed - indexed for MEDLINE] 

2:   Ette EI, Williams PJ. 
Population pharmacokinetics II: estimation methods.
Ann Pharmacother. 2004 Nov;38(11):1907-15. Epub 2004 Sep 14. Review. 
PMID: 15367729 [PubMed - indexed for MEDLINE]         

3:   Ette EI, Williams PJ. 
Population pharmacokinetics I: background, concepts, and models.
Ann Pharmacother. 2004 Oct;38(10):1702-6. Epub 2004 Aug 24. Review. 
PMID: 15328391 [PubMed - indexed for MEDLINE]
   
Warm Regards
 
Nitin Mehrotra
Dept. Pharmaceutical Sciences
UTHSC, Memphis, TN
_______________________________________________________